SlideShare a Scribd company logo
1 of 12
Download to read offline
Editorial Slides (B)
VP Watch – September 18, 2002 – Volume 1, Issue 37
Yet Another Reason to Eat Less Fat…
Provided by:
Mark Rekhter, Ph.D.
Pfizer Global Research and Development, Ann Arbor Labs
How Does Lipid Lowering Work?
Clinical trials have established that lipid lowering by statins
reduces acute coronary events.
Lipid lowering may do it via “stabilization” of plaques in a
functional manner, specifically by reducing vascular inflammation1
.
Oxidative stress (directly or through LDL modification) induces
endothelial cell expression of vascular cell adhesion molecule 1
(VCAM-1)2
and monocyte chemoattractant protein 1 (MCP-1)3
and
reduces levels of atheroprotective NO4
, leading to monocyte
recruitment and macrophage accumulation.
Can lipid lowering work through decreasing oxidative stress5
and
improving endothelial functions related to inflammatory cell
accumulation?
As reported in VP Watch of this week, Aikawa
et al6
. showed that dietary lipid lowering in a rabbit
model of atherosclerosis can reduce oxidative stress
and endothelial cell “activation” in vivo.
Thirty rabbits consumed an atherogenic diet for 4
months to create atheroma. Balloon injury of the
thoracic aortas was performed 1 week after initiation of
the diet. Fifteen rabbits euthanized at 4 months
constituted the BaselineBaseline group. Five animals continued
to consume atherogenic diet for additional 16 months
(High group). The remaining animals consumed a chow
diet with no added cholesterol and fat for 16 months
(Low group).
Lipid Accumulation and Oxidation
In hypercholesterolemic rabbits, apoB-100, a major
component of LDL and VLDL particles, accumulated in
atheroma and co-localized with oxLDL epitopes (detected by
the antibody against MDA-LDL).
Lipid lowering reduced the amount of immunoreactive
apoB-100 and LDL epitopes
Plasma levels of autoantibodies (IgG) against oxLDL
epitopes (MDA-LDL) in the Baseline and High groups
significantly exceeded those of the Low group.
Endothelial “Activation”
Cholesterol feeding was associated with increased VCAM-1
expression by endothelial cells overlaying atherosclerotic
lesions. Lipid lowering reduced VCAM-1 expression.
MCP-1 localized in endothelial cells, smooth muscle cells
and macrophages in atheroma of hypercholesterolemic
rabbits. Lipid lowering lead to significant reduction in MCP-1
expression.
Endothelial cells after lipid lowering exhibitied more
“normal” ultrastructure.
Lipid lowering reduced oxLDL
accumulation and VCAM-1
expression in rabbit atheroma.
A, OxLDL epitopes (MDA-lysine)
accumulated in the aortic intima
beneath VCAM-1–positive ECs in
hypercholesterolemic rabbits fed the
atherogenic diet for 4 months
(Baseline, top panels) or 20 months
(High, middle panels). Bottom panels,
oxLDL epitopes and VCAM-1 were
barely detectable in the intima of
rabbit aorta after 16 months of lipid
lowering (Low), whereas CD31, an EC
marker, indicated an intact monolayer.
Scale bar, 50 µmol/L.
B, Data for VCAM-1 are reported as
percentage of CD31-positive
endothelium also bearing VCAM-1
measured by computer-assisted color
image analysis. Bars represent SEM.
Endothelial NO Synthase (eNOS) Production
Endothelial cells in rabbit atheroma showed
less eNOS immunoreactivity than those in
normal aortas.
Low group rabbits showed more eNOS
positivity than hypercholesterolemic rabbits.
Reactive oxygen species (ROS) production
ROS production (detected as Tiron-inducible
lucigenin chemiluminescence) in freshly
isolated aortic segments from the Baseline- and
High-group rabbits exceeded that of aortas from
age-matched normal rabbits.
After 16 months of dietary lipid lowering, ROS
production decreased to levels similar to those
of the normal rabbits.
ROS production detected by lucigenin
chemiluminescence and NBT reducing
activity assay and plasma levels of
autoantibody against MDA-LDL.
A, Production of ROS including O2
-
(detected by lucigenin
chemiluminescence) in fresh aortic segments of high
cholesterol–fed rabbits from Baseline (n=6) and High
(n=5) groups significantly exceeded that of aortas of age-
matched normal rabbits (n=4). After 16 months of lipid
lowering (Low, n= 7), ROS production decreased to levels
similar to those of the normal rabbits. Bars, SEM.
B, Top panel, Aortic ECs of the Baseline group showed
intense reaction with NBT. Spindle-shaped cells (probably
SMCs) also stained blue with NBT. Middle panel, Cluster
of circular cells (likely macrophages) in the deeper intima
of the baseline lesion also stained blue with NBT. Bottom,
NBT staining was greatly reduced by cotreatment with the
cell-permeant superoxide scavenger Tiron (10 mmol/L).
Scale bar, 50 µmol/L.
C, Plasma levels of autoantibodies against oxLDL
epitopes (MDA-LDL) were measured by
chemiluminescence immunoassay. Levels of anti-MDA-
LDL IgG in the Baseline and High groups significantly
exceeded those of the Low group. Bars, SEM.
Conclusions:
Dietary lipid lowering can reduce oxidative
stress and endothelial “activation” in vivo.
These mechanisms may contribute to
improvement in endothelial function and plaque
stabilization observed clinically.
Questions
What is the mechanism of oxidative stress reduction
by dietary lipid lowering?
Is inhibition of ROS production a root cause of
endothelial “pacifying” or lipid lowering has multiple
independent effects on ROS, eNOS, MCP-1, etc.?
If lipid lowering is sufficient for restoration of
endothelial function and plaque stabilization, why
aggressive lipid lowering fails to eradicate heart attack?
Why anti-oxidants are not blockbusters yet?
What new drugs do we need: better lipid lowering
drugs, anti-oxidants or direct “endothelial pacifiers”?
References
1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
2. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM:
Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated
through an antioxidant-sensitive mechanism in human vascular endothelial cells. J.Clin.Invest.
1993, 92:1866-1874.
3. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ,
Fogelman AM: Minimally modified low density lipoprotein induces monocyte chemotactic
protein 1 in human endothelial cells and smooth muscle cells. Proceedings of the National
Academy of Sciences of the United States of America 1990, 87:5134-5138.
4. Espey MG, Miranda KM, Thomas DD, Xavier S, Citrin D, Vitek MP, Wink DA: A chemical
perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide
species. Annals of the New York Academy of Sciences 2002, 962:195-206.
5. Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG: Dietary correction
of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production.
Circulation 1995, 92:898-903.
6. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P:

More Related Content

What's hot

Plasma derived chemical mediators of inflammation - ttylim
Plasma derived chemical mediators of inflammation - ttylimPlasma derived chemical mediators of inflammation - ttylim
Plasma derived chemical mediators of inflammation - ttylimTty Lim
 
Systemic metabolic response to injures
Systemic metabolic response to injures  Systemic metabolic response to injures
Systemic metabolic response to injures salahudin ahadi
 
2.mnt for metabolic stress burn...
2.mnt for metabolic stress burn...2.mnt for metabolic stress burn...
2.mnt for metabolic stress burn...Wan Hazirah
 
Chemical Mediators of Acute Inflammation
Chemical Mediators of Acute InflammationChemical Mediators of Acute Inflammation
Chemical Mediators of Acute InflammationRawa Muhsin
 
Chemical mediators / dental implant courses
Chemical mediators / dental implant coursesChemical mediators / dental implant courses
Chemical mediators / dental implant coursesIndian dental academy
 
Inflammatory mediators- Pharmacology
Inflammatory mediators- PharmacologyInflammatory mediators- Pharmacology
Inflammatory mediators- PharmacologySanchit Dhankhar
 
13 chemical mediator of acute inflamation
13 chemical mediator of acute inflamation13 chemical mediator of acute inflamation
13 chemical mediator of acute inflamationDr UAK
 
Iso enzzyme by KK Sahu sir
Iso enzzyme by KK Sahu sirIso enzzyme by KK Sahu sir
Iso enzzyme by KK Sahu sirKAUSHAL SAHU
 
Inflammatory mediators
Inflammatory mediatorsInflammatory mediators
Inflammatory mediatorsRafa Zubair
 
Physiological Responses to Surgery & Trauma
Physiological Responses to Surgery & TraumaPhysiological Responses to Surgery & Trauma
Physiological Responses to Surgery & TraumaMuhammad Shoyab
 
Chemical Mediators of inflammation
Chemical Mediators of inflammationChemical Mediators of inflammation
Chemical Mediators of inflammationOmair Riaz
 

What's hot (19)

Plasma derived chemical mediators of inflammation - ttylim
Plasma derived chemical mediators of inflammation - ttylimPlasma derived chemical mediators of inflammation - ttylim
Plasma derived chemical mediators of inflammation - ttylim
 
Ecosinoids
EcosinoidsEcosinoids
Ecosinoids
 
Systemic metabolic response to injures
Systemic metabolic response to injures  Systemic metabolic response to injures
Systemic metabolic response to injures
 
2.mnt for metabolic stress burn...
2.mnt for metabolic stress burn...2.mnt for metabolic stress burn...
2.mnt for metabolic stress burn...
 
Chemical Mediators of Acute Inflammation
Chemical Mediators of Acute InflammationChemical Mediators of Acute Inflammation
Chemical Mediators of Acute Inflammation
 
Acute phase proteins
Acute phase proteinsAcute phase proteins
Acute phase proteins
 
Chemical mediators / dental implant courses
Chemical mediators / dental implant coursesChemical mediators / dental implant courses
Chemical mediators / dental implant courses
 
Inflammation
InflammationInflammation
Inflammation
 
Inflammatory mediators- Pharmacology
Inflammatory mediators- PharmacologyInflammatory mediators- Pharmacology
Inflammatory mediators- Pharmacology
 
Ecosinoid metabolism
Ecosinoid metabolismEcosinoid metabolism
Ecosinoid metabolism
 
Mediators of inflammation
Mediators of inflammationMediators of inflammation
Mediators of inflammation
 
13 chemical mediator of acute inflamation
13 chemical mediator of acute inflamation13 chemical mediator of acute inflamation
13 chemical mediator of acute inflamation
 
Isoenzymes
IsoenzymesIsoenzymes
Isoenzymes
 
Iso enzzyme by KK Sahu sir
Iso enzzyme by KK Sahu sirIso enzzyme by KK Sahu sir
Iso enzzyme by KK Sahu sir
 
Chemical mediators of inflammation
Chemical mediators of inflammationChemical mediators of inflammation
Chemical mediators of inflammation
 
1.sirs 060812
1.sirs 0608121.sirs 060812
1.sirs 060812
 
Inflammatory mediators
Inflammatory mediatorsInflammatory mediators
Inflammatory mediators
 
Physiological Responses to Surgery & Trauma
Physiological Responses to Surgery & TraumaPhysiological Responses to Surgery & Trauma
Physiological Responses to Surgery & Trauma
 
Chemical Mediators of inflammation
Chemical Mediators of inflammationChemical Mediators of inflammation
Chemical Mediators of inflammation
 

Viewers also liked (15)

АЦЦ®. Швидше за кашель
АЦЦ®. Швидше за кашельАЦЦ®. Швидше за кашель
АЦЦ®. Швидше за кашель
 
любовь
любовьлюбовь
любовь
 
2016 UN Forum on Business and Human Rights
2016 UN Forum on Business and Human Rights2016 UN Forum on Business and Human Rights
2016 UN Forum on Business and Human Rights
 
226 statins are overrated
226 statins are overrated226 statins are overrated
226 statins are overrated
 
Humanity
HumanityHumanity
Humanity
 
календар та реєстрація зно 2014
календар та реєстрація зно 2014календар та реєстрація зно 2014
календар та реєстрація зно 2014
 
How can business help tackle the refugee crisis
How can business help tackle the refugee crisisHow can business help tackle the refugee crisis
How can business help tackle the refugee crisis
 
Case Study Competition
Case Study CompetitionCase Study Competition
Case Study Competition
 
спарекс фарма
спарекс фармаспарекс фарма
спарекс фарма
 
АНФО (фармблок): Гептрaл
АНФО (фармблок): ГептрaлАНФО (фармблок): Гептрaл
АНФО (фармблок): Гептрaл
 
Handling Information
Handling InformationHandling Information
Handling Information
 
ICC Arbitration Statistics 2015
ICC Arbitration Statistics 2015ICC Arbitration Statistics 2015
ICC Arbitration Statistics 2015
 
The Five Forces Model by Michael E. Porter
The Five Forces Model by Michael E. PorterThe Five Forces Model by Michael E. Porter
The Five Forces Model by Michael E. Porter
 
Diaporama Conférence de Jancovici à Lyon - 22 novembre 2016
Diaporama Conférence de Jancovici à Lyon - 22 novembre 2016 Diaporama Conférence de Jancovici à Lyon - 22 novembre 2016
Diaporama Conférence de Jancovici à Lyon - 22 novembre 2016
 
Starting With Toyota 5s
Starting With Toyota 5sStarting With Toyota 5s
Starting With Toyota 5s
 

Similar to Esv2n37 b (20)

Distinguished Professor Lecture
Distinguished Professor LectureDistinguished Professor Lecture
Distinguished Professor Lecture
 
229 propagermanium
229 propagermanium229 propagermanium
229 propagermanium
 
229 propagermanium
229 propagermanium229 propagermanium
229 propagermanium
 
Esv2n24
Esv2n24Esv2n24
Esv2n24
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Tissue Injury
Tissue InjuryTissue Injury
Tissue Injury
 
Apomimetic peptides
Apomimetic peptides Apomimetic peptides
Apomimetic peptides
 
Adipokines in Insulin Resistance Current Updates.pptx
Adipokines in Insulin Resistance Current Updates.pptxAdipokines in Insulin Resistance Current Updates.pptx
Adipokines in Insulin Resistance Current Updates.pptx
 
Inflammation and oxidative stress: a clinical paradox
Inflammation and oxidative stress: a clinical paradox Inflammation and oxidative stress: a clinical paradox
Inflammation and oxidative stress: a clinical paradox
 
Guidelines for Good Management of Diabetes
Guidelines for Good Management of DiabetesGuidelines for Good Management of Diabetes
Guidelines for Good Management of Diabetes
 
109 anatomy of the atherosclerotic plaque
109 anatomy of the atherosclerotic plaque109 anatomy of the atherosclerotic plaque
109 anatomy of the atherosclerotic plaque
 
109 anatomy of the atherosclerotic plaque
109 anatomy of the atherosclerotic plaque109 anatomy of the atherosclerotic plaque
109 anatomy of the atherosclerotic plaque
 
1031 talk2
1031 talk21031 talk2
1031 talk2
 
1031 talk2
1031 talk21031 talk2
1031 talk2
 
Seminar 112108
Seminar 112108Seminar 112108
Seminar 112108
 
473410
473410473410
473410
 
Perez Cruz Et All 2003
Perez Cruz Et All 2003Perez Cruz Et All 2003
Perez Cruz Et All 2003
 
Mechanisms of LLLT/Anti-Aging_Hamblin_A4M_Orlando_2011
Mechanisms of LLLT/Anti-Aging_Hamblin_A4M_Orlando_2011Mechanisms of LLLT/Anti-Aging_Hamblin_A4M_Orlando_2011
Mechanisms of LLLT/Anti-Aging_Hamblin_A4M_Orlando_2011
 
3T3
3T33T3
3T3
 
Research Thesis
Research ThesisResearch Thesis
Research Thesis
 

More from Society for Heart Attack Prevention and Eradication

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 

Recently uploaded

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUKanhu Charan
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 

Recently uploaded (20)

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 

Esv2n37 b

  • 1. Editorial Slides (B) VP Watch – September 18, 2002 – Volume 1, Issue 37 Yet Another Reason to Eat Less Fat… Provided by: Mark Rekhter, Ph.D. Pfizer Global Research and Development, Ann Arbor Labs
  • 2. How Does Lipid Lowering Work? Clinical trials have established that lipid lowering by statins reduces acute coronary events. Lipid lowering may do it via “stabilization” of plaques in a functional manner, specifically by reducing vascular inflammation1 . Oxidative stress (directly or through LDL modification) induces endothelial cell expression of vascular cell adhesion molecule 1 (VCAM-1)2 and monocyte chemoattractant protein 1 (MCP-1)3 and reduces levels of atheroprotective NO4 , leading to monocyte recruitment and macrophage accumulation. Can lipid lowering work through decreasing oxidative stress5 and improving endothelial functions related to inflammatory cell accumulation?
  • 3. As reported in VP Watch of this week, Aikawa et al6 . showed that dietary lipid lowering in a rabbit model of atherosclerosis can reduce oxidative stress and endothelial cell “activation” in vivo. Thirty rabbits consumed an atherogenic diet for 4 months to create atheroma. Balloon injury of the thoracic aortas was performed 1 week after initiation of the diet. Fifteen rabbits euthanized at 4 months constituted the BaselineBaseline group. Five animals continued to consume atherogenic diet for additional 16 months (High group). The remaining animals consumed a chow diet with no added cholesterol and fat for 16 months (Low group).
  • 4. Lipid Accumulation and Oxidation In hypercholesterolemic rabbits, apoB-100, a major component of LDL and VLDL particles, accumulated in atheroma and co-localized with oxLDL epitopes (detected by the antibody against MDA-LDL). Lipid lowering reduced the amount of immunoreactive apoB-100 and LDL epitopes Plasma levels of autoantibodies (IgG) against oxLDL epitopes (MDA-LDL) in the Baseline and High groups significantly exceeded those of the Low group.
  • 5. Endothelial “Activation” Cholesterol feeding was associated with increased VCAM-1 expression by endothelial cells overlaying atherosclerotic lesions. Lipid lowering reduced VCAM-1 expression. MCP-1 localized in endothelial cells, smooth muscle cells and macrophages in atheroma of hypercholesterolemic rabbits. Lipid lowering lead to significant reduction in MCP-1 expression. Endothelial cells after lipid lowering exhibitied more “normal” ultrastructure.
  • 6. Lipid lowering reduced oxLDL accumulation and VCAM-1 expression in rabbit atheroma. A, OxLDL epitopes (MDA-lysine) accumulated in the aortic intima beneath VCAM-1–positive ECs in hypercholesterolemic rabbits fed the atherogenic diet for 4 months (Baseline, top panels) or 20 months (High, middle panels). Bottom panels, oxLDL epitopes and VCAM-1 were barely detectable in the intima of rabbit aorta after 16 months of lipid lowering (Low), whereas CD31, an EC marker, indicated an intact monolayer. Scale bar, 50 µmol/L. B, Data for VCAM-1 are reported as percentage of CD31-positive endothelium also bearing VCAM-1 measured by computer-assisted color image analysis. Bars represent SEM.
  • 7. Endothelial NO Synthase (eNOS) Production Endothelial cells in rabbit atheroma showed less eNOS immunoreactivity than those in normal aortas. Low group rabbits showed more eNOS positivity than hypercholesterolemic rabbits.
  • 8. Reactive oxygen species (ROS) production ROS production (detected as Tiron-inducible lucigenin chemiluminescence) in freshly isolated aortic segments from the Baseline- and High-group rabbits exceeded that of aortas from age-matched normal rabbits. After 16 months of dietary lipid lowering, ROS production decreased to levels similar to those of the normal rabbits.
  • 9. ROS production detected by lucigenin chemiluminescence and NBT reducing activity assay and plasma levels of autoantibody against MDA-LDL. A, Production of ROS including O2 - (detected by lucigenin chemiluminescence) in fresh aortic segments of high cholesterol–fed rabbits from Baseline (n=6) and High (n=5) groups significantly exceeded that of aortas of age- matched normal rabbits (n=4). After 16 months of lipid lowering (Low, n= 7), ROS production decreased to levels similar to those of the normal rabbits. Bars, SEM. B, Top panel, Aortic ECs of the Baseline group showed intense reaction with NBT. Spindle-shaped cells (probably SMCs) also stained blue with NBT. Middle panel, Cluster of circular cells (likely macrophages) in the deeper intima of the baseline lesion also stained blue with NBT. Bottom, NBT staining was greatly reduced by cotreatment with the cell-permeant superoxide scavenger Tiron (10 mmol/L). Scale bar, 50 µmol/L. C, Plasma levels of autoantibodies against oxLDL epitopes (MDA-LDL) were measured by chemiluminescence immunoassay. Levels of anti-MDA- LDL IgG in the Baseline and High groups significantly exceeded those of the Low group. Bars, SEM.
  • 10. Conclusions: Dietary lipid lowering can reduce oxidative stress and endothelial “activation” in vivo. These mechanisms may contribute to improvement in endothelial function and plaque stabilization observed clinically.
  • 11. Questions What is the mechanism of oxidative stress reduction by dietary lipid lowering? Is inhibition of ROS production a root cause of endothelial “pacifying” or lipid lowering has multiple independent effects on ROS, eNOS, MCP-1, etc.? If lipid lowering is sufficient for restoration of endothelial function and plaque stabilization, why aggressive lipid lowering fails to eradicate heart attack? Why anti-oxidants are not blockbusters yet? What new drugs do we need: better lipid lowering drugs, anti-oxidants or direct “endothelial pacifiers”?
  • 12. References 1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143. 2. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J.Clin.Invest. 1993, 92:1866-1874. 3. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:5134-5138. 4. Espey MG, Miranda KM, Thomas DD, Xavier S, Citrin D, Vitek MP, Wink DA: A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Annals of the New York Academy of Sciences 2002, 962:195-206. 5. Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG: Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995, 92:898-903. 6. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P: